ReviewThe oncologist2023
Management of Lung Cancer in the Patient with Interstitial Lung Disease.
Review in The oncologist, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 47 citations in OpenAlex.
- Integrated machine learning risk model for predicting radiation pneumonitis in lung cancer patients with interstitial lung disease.Annals of medicine · 2026Article
- [Surgical Management of Lung Cancer in Patients with Interstitial Lung Disease].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2026Review
- Surgical outcomes and prognoses of patients with clinical stage I lung cancer and interstitial lung disease.General thoracic and cardiovascular surgery · 2026Article
- Is Immunotherapy a Contraindication for Treating Lung Cancer Patients with Interstitial Lung Diseases? A Review of the Literature.Journal of clinical medicine · 2026Review
- Explosive multi-site metastasis temporally associated with acute exacerbation of idiopathic pulmonary fibrosis in a patient with surgically resected lung squamous cell carcinoma: a case report.Frontiers in medicine · 2026Article
- Lung cancer in patients with scleroderma-associated interstitial lung disease: Case series and implications for screening.Respiratory medicine case reports · 2026Article
- Clinical inflammatory shifts and peripheral flow-cytometry immune modules across benign pulmonary nodules, adenocarcinoma-spectrum nodules, and overt lung cancer.Frontiers in immunology · 2026Article
- Computed tomography imaging features of major pulmonary and extrapulmonary complications of fibrotic lung diseases.Einstein (Sao Paulo, Brazil) · 2026Review
- Interstitial lung abnormalities: to treat or not to treat? The hamlet dilemma.Frontiers in medicine · 2026Review
- Case report: Double-lung transplantation for Hermansky-Pudlak syndrome-associated pulmonary fibrosis and early-stage lung cancer.Frontiers in immunology · 2026Article
- Time-of-day radiotherapy alters radiation pneumonitis risk but not survival in lung cancer patients with interstitial lung disease.Therapeutic advances in medical oncology · 2026Article
- Inhibiting TROP2 in advanced non-small-cell lung cancer with sacituzumab govitecan, datopotamab deruxtecan, and sacituzumab tirumotecan: similarities and differences.Cancer chemotherapy and pharmacology · 2025Review
- Nintedanib enhances tumor cell radiosensitivity by promoting ferroptosis and modulating the ATF4/SLC7A11/GSH axis.Cancer biology & medicine · 2025Article
- Transbronchial Cryoablation for Early-Stage Non-Small Cell Lung Cancer of the Central Airway Complicated by Idiopathic Pulmonary Fibrosis.Respirology case reports · 2025Article
- Analysis of second-line therapy in patients with prior pneumonitis receiving first-line combination immunotherapy for advanced non-small cell lung cancer.Translational lung cancer research · 2025Article
- Concomitant Idiopathic Pulmonary Fibrosis and Lung Cancer: An Updated Narrative Review.Advances in respiratory medicine · 2025Review
- From Hypersensitivity Pneumonitis to Lung Adenocarcinoma: A Case Report Illustrating Diagnostic Complexity.Cureus · 2025Article
- Advancing understanding of autoimmune diseases and lung cancer: trends, themes, and future directions.Discover oncology · 2025Article
- Article
- Development of delayed pulmonary toxicities and transcriptional changes in pre-existing interstitial lung disease mice after partial thoracic irradiation.Radiation oncology (London, England) · 2025Article
Corrections and comments
- Erratum issued
Authors and funding
9 authors at 2 institutions in 2 countries.
Funding
Abstract
Patients with interstitial lung disease (ILD), especially those with pulmonary fibrosis, are at increased risk of developing lung cancer. Management of lung cancer in patients with ILD is particularly challenging. Diagnosis can be complicated by difficulty differentiating lung nodules from areas of focal fibrosis, and percutaneous biopsy approaches confer an increased risk of complications in those with pulmonary fibrosis. Lung cancer treatment in these patients pose several specific considerations. The degree of lung function impairment may preclude lobectomy or surgical resection of any type. Surgical resection can trigger an acute exacerbation of the underlying ILD. The presence of ILD confers an increased risk of pneumonitis with radiotherapy, and many of the systemic therapies also carry an increased risk of pneumonitis in this population. The safety of immunotherapy in the setting of ILD remains to be fully elucidated and concerns remain as to triggering pneumonitis. The purpose of this review is to summarize the evidence regarding consideration for tissue diagnosis, chemotherapy and immunotherapy, radiotherapy, and surgery, in this patient population and discuss emerging areas of research. We also propose a multidisciplinary approach and practical considerations for monitoring for ILD progression during lung cancer treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.